BFM
CBIO

Boothbay Fund Management’s Crescent Biopharma CBIO Stock Holding History

Boothbay Fund Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-456
Closed -$137K – 1659
2024
Q1 		$137K Buy
+456
New +$136K ﹤0.01% 1385

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's CBIO Position: Q1 2024 in Review

Boothbay Fund Management sold out of Crescent Biopharma (CBIO) in Q1 2024, closing a stake of 125 shares — an estimated $37.3K sold.

Boothbay Fund Management first reported a position in CBIO in Q3 2019 and held it in 3 quarters. The position peaked at $129K in Q3 2019. 69 funds tracked by Wall St. Rank hold CBIO as of Q1 2024.

  • Boothbay Fund Management reported no remaining Crescent Biopharma position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 125 Crescent Biopharma shares in Q1 2024, an estimated $37.3K.
  • Boothbay Fund Management first reported a position in Crescent Biopharma in Q3 2019 and held it in 3 quarters.
  • Boothbay Fund Management's Crescent Biopharma position peaked at $129K in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.